UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 28, 2009

NEOPROBE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	0-26520	31-1080091
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
425 Metro Place North, Suite 300, Columbus, Ohio		43017
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code (614) 793-7500

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On May 28, 2009, Neoprobe Corporation (the "Company") issued a press release announcing that a second multi-center Phase 3 study of Lymphoseek® (NEO3-06) has received investigational review board approval to begin enrollment of patients diagnosed with head and neck squamous cell carcinoma. Lymphoseek (Technetium Tc99m DTPA-mannosyl-dextran) is a proprietary radioactive lymphatic mapping targeting agent being developed by the Company for use with hand-held gamma detection devices in a surgical procedure known as Sentinel Lymph Node Biopsy. The Phase 3 study will evaluate the efficacy of Lymphoseek to identify sentinel lymph nodes that may be predictive of determining whether a patient's cancer has spread into the lymphatic system. The Phase 3 study has been registered on the national clinical trials website at www.clinicaltrials.gov. A copy of the complete text of the Company's May 28, 2009, press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Statements contained or incorporated by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	*Exhibit Description*
99.1	Neoprobe Corporation press release dated May 28, 2009, entitled "Neoprobe's Second Phase 3 Lymphoseek Study Commences."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Neoprobe Corporation

Date: May 28, 2009

By: /s/ Brent L. Larson
Brent L. Larson, Vice President, Finance and Chief Financial Officer

Exhibit 99.1

IMMEDIATE RELEASE **May 28, 2009**
CONTACTS: **Tim Ryan,**
Brent Larson, **The Shoreham Group**
Vice President / CFO **646 342 6199**
614 822 2330

NEOPROBE'S SECOND PHASE 3 LYMPHOSEEK STUDY COMMENCES
Clinical Study Evaluating Patients with Head and Neck Squamous Cell Carcinoma
Conference Call Scheduled to Discuss Trial

DUBLIN, OHIO – May 28, 2009 -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that a second multicenter Phase 3 study of Lymphoseek® (NEO3-06) has received investigational review board approval to begin enrollment of patients diagnosed with head and neck squamous cell carcinoma. The Phase 3 study will evaluate the efficacy of Lymphoseek to identify sentinel lymph nodes that may be predictive of determining whether a patient's cancer has spread into the lymphatic system. The Phase 3 study has been registered on the national clinical trials website www.clinicaltrials.gov.

David Bupp, Neoprobe's President and CEO, said, "Neoprobe is pleased to announce the initiation of its second Phase 3 study for Lymphoseek. This Phase 3 study, designated internally by Neoprobe as "Sentinel", is designed to validate Lymphoseek as a sentinel lymph node tracing agent. The trial will require the accrual of sixty (60) patients with confirmed lymph node disease. The initiation of the second Phase 3 study is a key milestone in the development of Lymphoseek for Neoprobe and we expect the achievement of additional milestones in the coming months."

Fredrick O. Cope, Ph.D., Neoprobe's Vice President, Drug Development and Clinical Research, said, "The Sentinel trial has the potential to favorably change the treatment of patients with the devastating diagnosis of head and neck squamous cell carcinoma. We are currently initiating clinical sites to enable them to begin patient enrollment in the study. In the coming months, additional sites will be initiated to commence patient enrollment including international sites. We expect a total of approximately thirty sites to participate in the trial." Richard C. Orahood, M.D., Neoprobe's Medical Director, added, "The commencement of the Sentinel trial, coupled with confirmation from the first Phase 3 study of Lymphoseek (NEO3-05) conducted in patients with either breast cancer or melanoma, signifies an important milestone for Neoprobe. The two Phase 3 studies are designed to support the new drug application (NDA) and FDA registration of Lymphoseek."

Neoprobe's President and CEO, David C. Bupp, and Vice President, Pharmaceutical Research and Clinical Development, Frederick O Cope, Ph.D., will discuss the Sentinel clinical study during a conference call scheduled for 11:00 AM EDT, June 1, 2009.

Conference Call Information			
TO PARTICIPATE LIVE:		**TO LISTEN TO A REPLAY:**	
Date:	June 1, 2009	Available until:	June 8, 2009
Time:	11:00AM ET	Toll-free (U.S.) Dial in # :	877-660-6853
		International Dial in # :	201-612-7415
Toll-free (U.S.) Dial in # :	877-407-8033	Replay pass codes (both required for playback):	
International Dial in # :	201-689-8033	Account # :	286
		Conference ID # :	324497

- more -

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.